Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2007 056 317.8 |
96 | EP file number | EAKZ | 14 19 8829.5 |
97 | EP publication number | EPN | 2898887 |
54 | Designation/title | TI | Kombination aus Telomerasehemmer und Gemcitabin zur Behandlung von Krebs |
51 | IPC main class | ICM (ICMV) | A61K 31/70 (2006.01) |
22 | DE application date | DAT | Oct 30, 2007 |
96 | EP application date | EAT | Oct 30, 2007 |
43 | Date of first publication | OT | Jul 29, 2015 |
| Date of publication of grant | PET | Sep 26, 2018 |
71/73 | Applicant/owner | INH | Geron Corp., Menlo Park, Calif., US |
72 | Inventor | IN | Go, Ning, Thousands Oaks, CA 91360, US; TRESSLER, Robert J., Capitola, CA 95010, US |
| Address for service | | Kilburn & Strode LLP, London WC1X 8NL, GB |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 855583 P Oct 30, 2006
|
| Due date | FT FG | Oct 31, 2025 Annual fee for the 19th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000002898887 Searchable text:
EP000002898887 Original document:
EP000002898887B1 Searchable text:
EP000002898887B1 |
43 | Date of first publication | EVT | Jul 29, 2015 |
| Date of the first transfer into DPMAregister | EREGT | Jul 30, 2015 |
| Date of the (most recent) update in DPMAregister | REGT | Sep 11, 2024 (Show all update days)(Hide all update days)- Sep 11, 2024
- Sep 19, 2023; Sep 14, 2022; Sep 29, 2021; Oct 23, 2020; Oct 23, 2019; Sep 19, 2019; Aug 15, 2019; Oct 23, 2018; Oct 6, 2018; Sep 15, 2018; Sep 13, 2018; May 9, 2018; Dec 7, 2017
- Historical data not available for this/these date(s)
- Jul 30, 2015
- Date of the first transfer into DPMAregister
|